Trials / Completed
CompletedNCT00151502
To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.
An 80-Week, Randomized, Multi-Center, Parallel-Group, Double-Blind Study of the Efficacy and Safety of Atorvastatin 80 MG Plus an Acetylcholinesterase Inhibitor Versus an Acetylcholinesterase Inhibitor Alone in the Treatment of Mild to Moderate Alzheimer's Disease.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 600 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 50 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out if atovastatin, when taken with a cholinesterase inhibitor, is effective for treating Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atorvastatin |
Timeline
- Start date
- 2002-11-01
- Completion
- 2007-07-01
- First posted
- 2005-09-09
- Last updated
- 2021-02-18
Locations
99 sites across 10 countries: United States, Australia, Austria, Canada, Denmark, Germany, South Africa, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00151502. Inclusion in this directory is not an endorsement.